click enter text
slightli weak ok decent grower next sever year
merck report financi result friday open
compani came broadli in-lin revenu ep us/consensu
gave revenu ep guidanc weaker
end slightli nervous ahead event
new pipelin news otherwis quiet set result
trim estim slightli even remain good rel
grower next sever year lower pt
bodi report full analysi
inform us/eu stock cover see
recent report outlook januari issu
monthli controversi report
trade fundament data
upsid target
factset/wolf research price feb
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday open merck
report result mostli in-lin consensu
gave revenu ep guidanc slightli weaker
announc hold investor event first long time june
overal impress deliv decent result in-lin expect importantli keytruda
came slightli ahead guidanc slightli weaker larg view clear event
investor anticip weak base mix messag come compani
recent weeks/month need continu invest busi claim pipelin good
ever disconnect rel investor percept eye mani includ us
late-stag pipelin thin rel spend roughli beg question much
heavi spend io crowd program someth seemingli happen
cite pipelin program like ebola vaccin dengu vaccin new improv
version pfe among other realli commerci hit interest
see say newly-announc june investor meet topic meantim
mrk depend keytruda grow ever higher brand set deliv continu strong growth
addit sourc long-term option upsid beyond high estim analyst alreadi
forecast alon enough carri stori view ye creat singl product concentr
risk may concern due time loe occur decad earli overli
concern realiti fact driver growth gardasil lynparza two exampl
term sale ep exhibit
revenu report vs consensu
non-gaap ep report vs consensu
keytruda sale vs consensu anoth solid quarter io execut
januvia/janumet sale vs consensu gardasil sale vs
consensu
revenu guid vs consensu
ep guid vs consensu
page
revenu decreas ep decreas
revenu estim declin ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas slightli vs prior repres
price target slightli lower vs prior repres unchang multipl
new slightli lower ep estim
gener prepar remark note
hold investor event june first time sever year
ex-u monotherapi lung key driver growth high express launch chemo combo select
eu also launch mel china
 key new driver growth brand either metastat set adjuv still
earli point develop keytruda despit indic alreadi hand mani
launch global yet monotherapi studi metastat diseas essenti complet huge set
opportun look forward esophag renal special highlight ex-u lung cancer launch
still earli day also excit tnbc wolf comment highlight adjuv
 updat neo-adjuv trial tnbc time character riski
trial low medium high relay opportun look earli data trial
share fda conclud import see data wait wolf comment
view suggest earli data like mix otherwis would talk adjuv opportun
declin give specif time character riski trial
 detail term penetr lung say still room
penetr us low biomark patient see rapid uptak
squamou segment ex-u growth high patient big opportun expand
broader biomark segment
page
 upcom renal cell data come abstract releas abstract much
 talk stage lung cancer trial trial say
begin concern pneumon give keytruda set radiotherapi
seek evalu see pneumon rate exce keytruda given stage fashion
patient receiv crt wolf comment mean trial rather trial specifi
sequenc treatment keytruda given follow crt avoid pneumon
 talk adjuv mel opportun also price keytruda wait adj mel
pdufa us wont comment us price specif ex-u favor price
 adjuv mel enjoy first-mov advantag alreadi share
compet admit alway good first note bladder launch
lead market share strong data oncologist look first foremost strength data
say mel data strong commun oncolog set strong presenc renal cell
remind top line os benefit among thing believ posit well
 talk depend one product defend keytruda-onli
stori mani brand contribut growth seek augment busi
 keytruda sale indic us nsclc mel bladder high
exu major lung cancer
 outlin like pace share gain lung eu say reimburs eu
monotherapi reimburs hand countri
advanc throughout year also highlight ja opportun note
earli stage china mel launch
intern china drive growth along gender-neutr vaccin femal male roll-
variou market
 get breakthrough therapi design children adult said data
meaning pediatr strong data adult realli matter time discuss
agenc
 updat litig freedom oper say
freedom oper note litig continu
page
 investor miss think pipelin thin answer describ
expans in-lin brand indic expans describ variou early-stag asset
 may share common thread heavi io spend crowd
rest pipelin context keytruda spend peak note bulk clinic
 spend inde keytruda combin monotherapi point suggest
spend keytruda also lynparza/lenvima peak next coupl year howev compani
keep turn new stone find area invest gener
 look therapeut area outsid oncolog main goal improv
patient health bound one ta cite hiv area make headway put
lot effort well area like infecti diseas
view key pillar mrk futur growth wolf comment read dont hold breath wait spin
growth guidanc exclud fx fairli flat share
outstand inc/exp roughli zero equiti gains/loss neg impact
wolf comment recal pfe unexpect decis exclud equiti gains/loss
 think rang deal size focu etc doesnt pre-determin
therapeut area best remain opportunist look deal
licens acquisit partner etc note balanc sheet strong look entir spectrum
asset ta seek add deal dont disrupt thu continu mega-merg
 long-term opex spend trajectori still guid long-term oper margin expans
also note lot opportunity/ne invest busi next coupl year spend
outpac sale growth note show margin expans manag sg
tightli wolf comment captur common trend among compani tighten sg
spend continu creep
 go back oper margin expans discuss abil streamlin cost structur
futur year say sg continu get better sale note headwind gross margin
line margin expans realli come sg
assum net price us guidanc assum contribut price
 view new rebat propos hh share administr goal
lower pocket spend consum say skew system mean middl men contribut high
page
exhibit show compani report actual result vs estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
newoldnewtot incl marginin-lin bpssg amanag grow faster sale expenseshigh low- mid-singl digit rate guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
product revenu daili total isentress remicad simponi zepati biosimilar viral vaccin proquad varivax pneumovax comvax pedvaxhib gardasil januvia dulera allergi women bridion keytruda onc pain product earli phase revenu incl lynparza total
exhibit wr merck balanc sheet cash flow statement
page
flow statement incom incom distribut equiti incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
